Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma

Video Series

Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options 

Video content above is prompted by the following:

How would you compare ide-cel and cilta-cel in terms of patient selection?

Are there specific patient characteristics that might make you lean towards one CAR-T product over the other?

How do the efficacy and safety profiles of these two products influence your decision-making for different patient groups?

Meeting of the Minds video series features an actor portrayal of a hypothetical patient profile developed for educational purposes by leading oncology experts, based on characteristics of patients with various cancer types as seen in clinical practice.

This video episode follows the journey of a 55-year-old female tech CEO with multiple myeloma, highlighting her treatments, relapse challenges, and transition to ide-cel, supported by her active lifestyle and strong support network.

Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel  

Medical experts examine the factors that make Sarah an ideal candidate for CAR-T therapy in the second-line setting, focusing on how her age, fitness, and early relapse influence treatment decisions and exploring alternative options.

Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

This video episode explores data supporting ide-cel in the second-line setting for multiple myeloma, highlighting key findings from the KarMMa and KarMMa-3 trials, comparisons to other options, and clinical experiences regarding efficacy, quality of life benefits, and implementation challenges.

Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma 

This video episode examines decision-making between CAR-T therapy and novel agents in the second-line setting, scenarios for preferring alternative therapies, and treatment strategies following progression after ide-cel, emphasizing the impact of prior CAR-T therapy on subsequent choices.

Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

This video episode highlights the journey of a 72-year-old retired science teacher with multiple myeloma, covering his treatments, relapse, management of comorbidities, and transition to cilta-cel, supported by his active and healthy wife.

Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

This video episode explores treatment decisions for second-line therapy in a patient with age and comorbidities, reviews cilta-cel data from the CARTITUDE trials, and discusses clinical experience with cilta-cel, emphasizing efficacy, quality of life, and adaptations for complex patient profiles.

Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

This video episode compares ide-cel and cilta-cel for patient selection, examining specific characteristics, efficacy and safety profiles, and their influence on treatment decisions across diverse patient groups.

Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP: 2.Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

EP: 3.Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

EP: 4.Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

EP: 6.Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

EP: 7.Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options